Clinical trial
clinical trial
Paclitaxel with or without carboplatin and/or bevacizumab followed by doxorubicin and cyclophosphamide in treating patients with breast cancer that can be removed by surgery
Intervention
Drug intervention
Intervention Type
drug intervention
has_intervention
Carboplatin
drug intervention
Carboplatin
Intervention
intervention
planned process
planned process
process
occurrent
entity
Drug intervention
drug intervention
Bevacizumab
drug intervention
Bevacizumab
Intervention
intervention
planned process
planned process
process
occurrent
entity
Drug intervention
drug intervention
Doxorubicin
drug intervention
Doxorubicin
Intervention
intervention
planned process
planned process
process
occurrent
entity
Drug intervention
drug intervention
Cyclophosphamide
drug intervention
Cyclophosphamide
Intervention
intervention
planned process
planned process
process
occurrent
entity
Drug intervention
drug intervention
Paclitaxel
drug intervention
Paclitaxel
Intervention
intervention
planned process
planned process
process
occurrent
entity
Drug intervention
drug intervention
Antineoplastic combined chemotherapy
drug intervention
Antineoplastic combined chemotherapy
Intervention
intervention
planned process
planned process
process
occurrent
entity
Contact
has contact
has_contact
Berenberg, Jeffrey
PI
has PI
has_PI
Topic
has topic
has_topic
breast cancer
Funded by
funded by
funded_by
Cancer Trials Support Unit
Phase
Phase 2 clinical trial
has phase
has_phase
Phase 2
Performed by
human study performed by
human_study_performed_by
Clinical Protocol & Data Management Shared Resource
http://www.clinicaltrials.gov/ct2/show/NCT00861705?term=NCT00861705&rank=1
ClinicalTrials.gov url
ClinicalTrials.gov url
CTurl
This randomized phase II trial is studying how well giving paclitaxel with or without carboplatin and/or bevacizumab followed by doxorubicin and cyclophosphamide works in treating patients with breast cancer that can be removed by surgery.
Resource Description
resource_description
Randomized phase II 2 x 2 factorial trial of the addition of carboplatin +/- bevacizumab to neoadjuvant weekly paclitaxel followed by dose-dense ACc in hormone receptor-poor/HER2-negative resectable breast cancer
Additional Name
eagle-i_synonym
At least 18 years old Stage II or stage IIIA breast cancer Measurable disease HER2-negative, estrogen receptor-negative (ER-), and progesterone receptor-negative (PR-) tumor More than 4 weeks since surgery No previous chemotherapy, hormone therapy, or radiation therapy for this cancer For more information about the eligibility criteria for this trial, refer to the Health Professional version. For more information about the eligibility criteria for this trial, refer to the Health Professional version.
Study Population
study population
has_study_population
2011-06-27T19:28:13.388-05:00
awendicke (Annemarie Wendicke)
2011-09-23T10:59:43.076-05:00
workflow state
Published
mwilson (Melanie Wilson)
nvasilevsky
Interventional study
Research project
research project
Human Study
human study
human study
planned process
planned process
Quantitative human study
process
occurrent
entity